A Study to Determine the Safety & Efficacy of Autologous Human Platelet Lysate (HPL) in Treatment of Dark Circles
NCT ID: NCT01644448
Last Updated: 2012-07-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
20 participants
INTERVENTIONAL
2012-03-31
2012-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study arm A
Subjects will receive one dose of 5 ml of Autologous Human Platelet Lysate with simultaneous micro-needling on day 2
Autologous Human Platelet Lysate
Subjects will receive one dose of 5 ml of HPL with simultaneous micro-needling on day 2
Control Arm B
Topical Applications of the standard therapy as directed by the investigator
Standard Therapy
Topical Applications as directed by the investigator
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Autologous Human Platelet Lysate
Subjects will receive one dose of 5 ml of HPL with simultaneous micro-needling on day 2
Standard Therapy
Topical Applications as directed by the investigator
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject willing to refrain from any other treatment of Periorbital Hyperpigmentation during entire study duration.
* Subjects who are willing to give informed consent and adhere to the study protocol.
Exclusion Criteria
* Subjects with history of connective tissue disease.
* Subjects with metabolic or hematopoietic disorders
* Subjects unwilling to or unable to comply with the study protocol.
* Subjects taking concomitant therapy that might interfere with the study results in the investigator's opinion or participating in another trial in the past 30 days.
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kasiak Research Pvt. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Farida Modi, Dr.
Role: PRINCIPAL_INVESTIGATOR
Dermacare
Preeti Savardekar, Dr.
Role: PRINCIPAL_INVESTIGATOR
Shree Krishna Polyclinic
Sharmila Patil, Dr.
Role: PRINCIPAL_INVESTIGATOR
Dr. Sharmila's Dermocosmetic laser center, hair and skin clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kasiak Research Pvt Ltd
Thāne, Maharashtra, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KRPL/HPL-FR/11-12/002A
Identifier Type: -
Identifier Source: org_study_id